CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CRL - US1598641074 - Common Stock
216.48 USD
+0.09 (+0.04%)
We assign a fundamental rating of 4 out of 10 to CRL. CRL was compared to 57 industry peers in the Life Sciences Tools & Services industry. CRL has an average financial health and profitability rating. CRL has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- In the past year CRL was profitable.
- In the past year CRL had a positive cash flow from operations.
- CRL had positive earnings in each of the past 5 years.
- In the past 5 years CRL always reported a positive cash flow from operatings.
1.2 Ratios
- CRL has a Return On Assets of -1.11%. This is comparable to the rest of the industry: CRL outperforms 57.89% of its industry peers.
- CRL's Return On Equity of -2.45% is in line compared to the rest of the industry. CRL outperforms 59.65% of its industry peers.
- CRL has a Return On Invested Capital of 5.84%. This is in the better half of the industry: CRL outperforms 73.68% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for CRL is significantly below the industry average of 13.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.11% | ||
| ROE | -2.45% | ||
| ROIC | 5.84% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
1.3 Margins
- CRL's Profit Margin has declined in the last couple of years.
- With a decent Operating Margin value of 11.73%, CRL is doing good in the industry, outperforming 71.93% of the companies in the same industry.
- CRL's Operating Margin has been stable in the last couple of years.
- CRL has a Gross Margin of 34.68%. This is in the lower half of the industry: CRL underperforms 61.40% of its industry peers.
- In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.73% | ||
| PM (TTM) | N/A | ||
| GM | 34.68% |
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CRL is destroying value.
- Compared to 1 year ago, CRL has less shares outstanding
- The number of shares outstanding for CRL has been increased compared to 5 years ago.
- Compared to 1 year ago, CRL has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 2.73 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
- The Altman-Z score of CRL (2.73) is better than 63.16% of its industry peers.
- The Debt to FCF ratio of CRL is 4.02, which is a neutral value as it means it would take CRL, 4.02 years of fcf income to pay off all of its debts.
- With a decent Debt to FCF ratio value of 4.02, CRL is doing good in the industry, outperforming 75.44% of the companies in the same industry.
- A Debt/Equity ratio of 0.64 indicates that CRL is somewhat dependend on debt financing.
- CRL has a worse Debt to Equity ratio (0.64) than 71.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.64 | ||
| Debt/FCF | 4.02 | ||
| Altman-Z | 2.73 |
ROIC/WACC0.55
WACC10.65%
2.3 Liquidity
- A Current Ratio of 1.37 indicates that CRL should not have too much problems paying its short term obligations.
- CRL's Current ratio of 1.37 is on the low side compared to the rest of the industry. CRL is outperformed by 78.95% of its industry peers.
- CRL has a Quick Ratio of 1.10. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
- CRL's Quick ratio of 1.10 is on the low side compared to the rest of the industry. CRL is outperformed by 73.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
- CRL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.25%.
- Measured over the past years, CRL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.93% on average per year.
- CRL shows a decrease in Revenue. In the last year, the revenue decreased by -0.92%.
- The Revenue has been growing by 9.09% on average over the past years. This is quite good.
EPS 1Y (TTM)4.25%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%-6.18%
Revenue 1Y (TTM)-0.92%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-0.49%
3.2 Future
- CRL is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.56% yearly.
- Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 2.25% on average per year.
EPS Next Y0.17%
EPS Next 2Y3.1%
EPS Next 3Y5.39%
EPS Next 5Y6.56%
Revenue Next Year-0.56%
Revenue Next 2Y0.55%
Revenue Next 3Y1.91%
Revenue Next 5Y2.25%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- CRL is valuated rather expensively with a Price/Earnings ratio of 20.52.
- CRL's Price/Earnings ratio is rather cheap when compared to the industry. CRL is cheaper than 91.23% of the companies in the same industry.
- CRL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.33.
- Based on the Price/Forward Earnings ratio of 19.73, the valuation of CRL can be described as rather expensive.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 91.23% of the companies listed in the same industry.
- CRL's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.12.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.52 | ||
| Fwd PE | 19.73 |
4.2 Price Multiples
- 91.23% of the companies in the same industry are more expensive than CRL, based on the Enterprise Value to EBITDA ratio.
- 89.47% of the companies in the same industry are more expensive than CRL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.6 | ||
| EV/EBITDA | 14.05 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CRL does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)123.42
PEG (5Y)2.3
EPS Next 2Y3.1%
EPS Next 3Y5.39%
5. Dividend
5.1 Amount
- No dividends for CRL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:CRL (1/15/2026, 3:35:56 PM)
216.48
+0.09 (+0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-17 2026-02-17/amc
Inst Owners107.25%
Inst Owner Change0.49%
Ins Owners0.89%
Ins Owner Change0.17%
Market Cap10.66B
Revenue(TTM)4.02B
Net Income(TTM)-83.48M
Analysts79.09
Price Target201.38 (-6.98%)
Short Float %4.95%
Short Ratio2.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.28%
Min EPS beat(2)2.88%
Max EPS beat(2)23.68%
EPS beat(4)4
Avg EPS beat(4)10.51%
Min EPS beat(4)2.88%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.19%
EPS beat(12)12
Avg EPS beat(12)8.5%
EPS beat(16)16
Avg EPS beat(16)6.77%
Revenue beat(2)2
Avg Revenue beat(2)2.06%
Min Revenue beat(2)0.38%
Max Revenue beat(2)3.74%
Revenue beat(4)4
Avg Revenue beat(4)2.12%
Min Revenue beat(4)0.38%
Max Revenue beat(4)3.74%
Revenue beat(8)7
Avg Revenue beat(8)1.53%
Revenue beat(12)10
Avg Revenue beat(12)1.83%
Revenue beat(16)12
Avg Revenue beat(16)1.25%
PT rev (1m)4.22%
PT rev (3m)10.19%
EPS NQ rev (1m)0.04%
EPS NQ rev (3m)-2.03%
EPS NY rev (1m)0.01%
EPS NY rev (3m)0.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.52 | ||
| Fwd PE | 19.73 | ||
| P/S | 2.65 | ||
| P/FCF | 19.6 | ||
| P/OCF | 14.22 | ||
| P/B | 3.13 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.05 |
EPS(TTM)10.55
EY4.87%
EPS(NY)10.97
Fwd EY5.07%
FCF(TTM)11.05
FCFY5.1%
OCF(TTM)15.23
OCFY7.03%
SpS81.75
BVpS69.19
TBVpS-1.79
PEG (NY)123.42
PEG (5Y)2.3
Graham Number128.16
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.11% | ||
| ROE | -2.45% | ||
| ROCE | 7.39% | ||
| ROIC | 5.84% | ||
| ROICexc | 6.03% | ||
| ROICexgc | 13.86% | ||
| OM | 11.73% | ||
| PM (TTM) | N/A | ||
| GM | 34.68% | ||
| FCFM | 13.51% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexgc growth 3Y-14.69%
ROICexgc growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score4
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.64 | ||
| Debt/FCF | 4.02 | ||
| Debt/EBITDA | 2.43 | ||
| Cap/Depr | 48.19% | ||
| Cap/Sales | 5.12% | ||
| Interest Coverage | 4.36 | ||
| Cash Conversion | 83.34% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 2.73 |
F-Score4
WACC10.65%
ROIC/WACC0.55
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)4.25%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%-6.18%
EPS Next Y0.17%
EPS Next 2Y3.1%
EPS Next 3Y5.39%
EPS Next 5Y6.56%
Revenue 1Y (TTM)-0.92%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-0.49%
Revenue Next Year-0.56%
Revenue Next 2Y0.55%
Revenue Next 3Y1.91%
Revenue Next 5Y2.25%
EBIT growth 1Y-22.72%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year29.81%
EBIT Next 3Y11.7%
EBIT Next 5Y9.91%
FCF growth 1Y47.54%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y7.42%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%
CHARLES RIVER LABORATORIES / CRL FAQ
What is the fundamental rating for CRL stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRL.
What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?
ChartMill assigns a valuation rating of 5 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.
How profitable is CHARLES RIVER LABORATORIES (CRL) stock?
CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for CRL stock?
The Earnings per Share (EPS) of CHARLES RIVER LABORATORIES (CRL) is expected to grow by 0.17% in the next year.